Oric Pharmaceuticals, Inc.
ORIC
Positions held
Your positionsORIC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Oric Pharmaceuticals operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- The company has a market cap of approximately $1.24 billion, indicating a strong position in the market.
- Analysts have given Oric a 'strong buy' recommendation, reflecting positive sentiment about its future prospects.
- Oric Pharmaceuticals has reported negative net income for multiple consecutive quarters, with a net loss of -41.492 million in Q2 2026.
- The company has not generated any revenue in the last several quarters, consistently reporting zero revenue.
- Oric's operating income has been negative, with a loss of -45.296 million in Q2 2026, highlighting ongoing financial challenges.
Fundamentals
| Market cap | $1.25B | Enterprise value | $988.18M | Trailing P/E | — | Forward P/E | -7.19 |
| PEG | — | Price / book | 3.27 | Beta | 0.98 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -39.8% | ROA | -26.0% | Debt / equity | 0.02 |
| Current ratio | 13.19 | Free cash flow | -$68.83M | Analyst recommendation | strong_buy | Mean target | $21.43 |
| 52w high | $14.68 | 52w low | $7.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$41.5M | -$35.8M | -$30.5M | -$32.6M | -$36.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$45.3M | -$39.6M | -$34.6M | -$36.7M | -$39.1M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$129M | -$128M | -$101M | -$89.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$143M | -$143M | -$111M | -$86.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
2026-10-05 · Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target
2026-10-02 · ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-23 · BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target
2026-09-15 · ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
2026-09-04 · ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-08-28 · Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing
2026-08-07 · ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-07 · Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
2026-08-03 · ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Price (daily)
Full chart · RSI · MACD · patterns